Adaptimmune Therapeutics plc

  • Home
  • Our Company
    • Overview arrow_forward
    • Partners arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
    • Scientific Advisory Board arrow_forward
    • Perspectives arrow_forward
  • Pipeline
    • Clinical Pipeline arrow_forward
    • Afami-cel arrow_forward
    • ADP-A2M4CD8 arrow_forward
    • Preclinical Pipeline arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Cancer Info arrow_forward
    • Videos arrow_forward
    • Engagement with Patient Organizations arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
Aug 01, 2019 7:15am EDT

Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

Jul 29, 2019 4:05pm EDT

Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019

Jul 25, 2019 8:00am EDT

Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

Jul 22, 2019 8:00am EDT

Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center

Jul 18, 2019 8:00am EDT

Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses

Jun 27, 2019 8:00am EDT

Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

May 15, 2019 8:00am EDT

Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products

May 06, 2019 7:30am EDT

Adaptimmune Reports First Quarter 2019 Financial Results

May 06, 2019 7:00am EDT

Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors

May 02, 2019 7:00am EDT

Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting

RSS
  • Prev
  • 1...
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • ...25
  • Next
Adaptimmune Therapeutics plc
Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2023 Adaptimmune Therapeutics plc. All Rights Reserved.